|
|||||
|
|
TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial |
|
| Authors: | J M S Bartlett T O Nielsen D Gao K A Gelmon M A Quintayo J Starczynski L Han M J Burnell M N Levine B E Chen L E Shepherd J W Chapman |
| Abstract: | |
| Keywords: | breast cancer adjuvant TLE3 taxane |